Johnson & Johnson
JNJ
NYSE
Pharmaceuticals
$267.37
USD
-6.04 (-2.21%)
At close: Aug 20, 2026, 4:00 PM EDT
Market Cap $629.71B
Volume 6.5M
Revenue
$97.93B
TTM
+8.1%
YoY
Gross Margin
68%
TTM
-0.0%
YoY
Net Income
$21.04B
TTM
-7.2%
YoY
Operating Cash Flow
$27.61B
TTM
+19.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 23,743.0 | 23,993.0 | 24,564.0 | 24,062.0 | 25,310.0 |
YoY Growth | +5.8% | +6.8% | +9.1% | +9.9% | +6.6% |
Cost of Revenue | 7,628.0 | 7,303.0 | 7,968.0 | 8,106.0 | 8,051.0 |
Gross Profit | 16,115.0 | 16,690.0 | 16,596.0 | 15,956.0 | 17,259.0 |
Selling, General & Administrative | 5,889.0 | 5,922.0 | 6,753.0 | 6,034.0 | 6,432.0 |
Other Operating Expenses | 64.0 | 63.0 | 84.0 | 32.0 | 34.0 |
Total Operating Expenses | 9,469.0 | 9,657.0 | 11,170.0 | 9,629.0 | 10,119.0 |
Operating Income | 6,646.0 | 7,033.0 | 5,426.0 | 6,327.0 | 7,140.0 |
EBITDA | 8,653.0 | 8,873.0 | 7,521.0 | 8,363.0 | 9,133.0 |
Other Income / Expense | -107.0 | 478.0 | -483.0 | -294.0 | -331.0 |
Total Other Income / Expense | -155.0 | 460.0 | -460.0 | -337.0 | -393.0 |
Income Before Income Taxes | 6,491.0 | 7,493.0 | 4,966.0 | 5,990.0 | 6,747.0 |
Income Taxes | 954.0 | 2,341.0 | -150.0 | 755.0 | 1,213.0 |
Net Income | 5,537.0 | 5,152.0 | 5,116.0 | 5,235.0 | 5,534.0 |
Consolidated Net Income / Loss | 5,537.0 | 5,152.0 | 5,116.0 | 5,235.0 | 5,534.0 |
Net Income Attributable to Common Shareholders | 5,537.0 | 5,152.0 | 5,116.0 | 5,235.0 | 5,534.0 |
Basic EPS | $2.30 | $2.14 | $2.12 | $2.17 | $2.30 |
Diluted EPS | $2.29 | $2.12 | $2.09 | $2.14 | $2.27 |
Basic Shares Outstanding | 2,406.3M | 2,408.3M | 2,407.8M | 2,408.7M | 2,407.4M |
Diluted Shares Outstanding | 2,419.1M | 2,428.6M | 2,446.1M | 2,445.2M | 2,440.1M |